secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001062822-23-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon reports Q2 net loss $44.9M; FDA-approved INPEFA launched, LX9211 advancing
--------------------------------------------------------------------------------

- FDA approved INPEFA (sotagliflozin) for heart failure across full LVEF range; U.S. launch completed within 30 days.
- LX9211 moving into late-stage development for DPNP; Phase 2b dose optimization study starts Q3 2023.
- Q2 2023 net loss of $44.9M ($0.22 per share) vs $24.6M ($0.16) in Q2 2022.
- SG&A expenses rose to $30.0M from $10.7M due to commercial launch preparations; R&D $14.5M vs $13.4M.
- Cash and investments $256.7M as of June 30, 2023, up from $138.4M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/0001062822-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000045/lxrx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001062822-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer